A5084463088- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Multiple Myeloma Research and Treatments
- Chromatin Remodeling and Cancer
- Cancer Mechanisms and Therapy
- RNA Interference and Gene Delivery
- Cancer-related molecular mechanisms research
- Histone Deacetylase Inhibitors Research
- MicroRNA in disease regulation
- Advanced biosensing and bioanalysis techniques
- interferon and immune responses
- Ubiquitin and proteasome pathways
- Circular RNAs in diseases
- Immunotherapy and Immune Responses
- Cancer-related gene regulation
- Immune Cell Function and Interaction
- MXene and MAX Phase Materials
- PI3K/AKT/mTOR signaling in cancer
- RNA Research and Splicing
- RNA modifications and cancer
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Phagocytosis and Immune Regulation
- Lung Cancer Research Studies
- Chemokine receptors and signaling
- Cellular transport and secretion
Candiolo Cancer Institute
2023-2025
Dana-Farber Cancer Institute
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
Harvard University
2015-2024
Brigham and Women's Hospital
2024
Dana-Farber Brigham Cancer Center
2024
Heidelberg University
2023
University Hospital Heidelberg
2023
Josep Carreras Leukaemia Research Institute
2023
Institut Català d'Oncologia
2023
Deregulated expression of miRNAs has been shown in multiple myeloma (MM). A promising strategy to achieve a therapeutic effect by targeting the miRNA regulatory network is enforce that act as tumor suppressor genes, such miR-34a.Here, we investigated potential synthetic miR-34a against human MM cells vitro and vivo.Either transient mimics or lentivirus-based miR-34a-stable enforced triggered growth inhibition apoptosis vitro. Synthetic downregulated canonic targets BCL2, CDK6, NOTCH1 at both...
Abstract Purpose: Deregulated expression of miRNAs plays a role in the pathogenesis and progression multiple myeloma. Among upregulated miRNAs, miR-21 has oncogenic potential therefore represents an attractive target for treatment Experimental Design: Here, we investigated vitro vivo anti-multiple myeloma activity inhibitors. Results: Either transient-enforced or lentivirus-based constitutive inhibitors triggered significant growth inhibition primary patient cells...
MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple myeloma (MM) through the modulation of still undiscovered molecular pathways. Here, we investigated effects enforced expression miR-29b on apoptotic occurrence MM and highlighted its role context a new transcriptional loop that is finely tuned by proteasome inhibitor bortezomib. In details, vitro growth inhibition apoptosis cells was induced either transient synthetic or stable...
Aberrant DNA methylation plays a relevant role in multiple myeloma (MM) pathogenesis. MicroRNAs (miRNAs) are class of small non-coding RNAs that recently emerged as master regulator gene expression by targeting protein-coding mRNAs. However, miRNAs involvement the regulation epigenetic machinery and their potential use therapeutics MM remain to be investigated. Here, we provide evidence de novo methyltransferases (DNMTs) is deregulated cells. Moreover, show miR-29b targets DNMT3A DNMT3B...
// Maria Teresa Di Martino 1,2 , Annamaria Gullà 1 Eugenia Gallo Cantafio Marta Lionetti 3 Emanuela Leone Nicola Amodio Pietro Hiram Guzzi 4 Umberto Foresta Francesco Conforti 2 Mario Cannataro Antonino Neri Antonio Giordano 5,6 Pierosandro Tagliaferri and Pierfrancesco Tassone 1,2,6 Department of Experimental Clinical Medicine, Magna Graecia University, Catanzaro, Italy Medical Oncology, Tommaso Campanella Cancer Center, Sciences University Milan, Hematology1, IRCCS Policlinico Foundation,...
Multiple myeloma (MM) is a disease with an adverse outcome and new therapeutic strategies are urgently awaited. A rising body of evidence supports the notion that microRNAs (miRNAs), master regulators eukaryotic gene expression, may exert anti-MM activity. Here, we evaluated activity synthetic miR-34a in MM cells. We found transfection mimics cells induces significant change expression relevant effects on multiple signal transduction pathways. detected early inactivation pro-survival...
The onset of drug resistance is a major cause treatment failure in multiple myeloma. Although increasing evidence defining the role miRNAs mediating resistance, their potential activity as drug-sensitizing agents has not yet been investigated
Over the past 20 years, regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 8-10 years. Increased understanding MM biology translated advances in diagnosis, prognosis, and response assessment, as well informed development targeted immune agents. Here we provide an overview recent progress MM, highlight research areas greatest promise further improve outcome future.
Interferon regulatory factor 4 (IRF4) is an attractive therapeutic target in multiple myeloma (MM). We here report that expression of IRF4 mRNA inversely correlates with microRNA (miR)-125b MM patients. Moreover, we provide evidence miR-125b downregulated TC2/3 molecular subgroups and established cell lines. Importantly, constitutive miR-125b-5p by lentiviral vectors or transfection synthetic mimics impaired growth survival cells overcame the protective role bone marrow stromal vitro....
Abstract Epigenetic abnormalities are common in hematologic malignancies, including multiple myeloma, and their effects can be efficiently counteracted by a class of tumor suppressor miRNAs, named epi-miRNAs. Given the oncogenic role histone deacetylases (HDAC) we investigated whether activity could antagonized miR-29b, well-established epi-miRNA. We demonstrated here that miR-29b specifically targets HDAC4 highlighted both molecules involved functional loop. In fact, silencing shRNAs...
Abstract The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using vitro as well vivo immunodeficient immunocompetent murine models, we here show that also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying cells, phagocytosis tumor dendritic induction myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome two independent...
// Maria Rita Pitari 1 , Marco Rossi Nicola Amodio Cirino Botta Eugenio Morelli Cinzia Federico Annamaria Gullà Daniele Caracciolo Teresa Di Martino Mariamena Arbitrio 2 Antonio Giordano 3, 4 Pierosandro Tagliaferri Pierfrancesco Tassone 1, Department of Experimental and Clinical Medicine T. Campanella Cancer Center, Magna Graecia University, S. Venuta University Campus, Catanzaro, Italy ISN-CNR, Roccelletta di Borgia, 3 Human Pathology Oncology, Siena, Sbarro Institute for Research...
Abstract Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this poorly understood. Here, we identify, via two vitro genome-wide CRISPR screens probing resistance, KDM6A as an important regulator of sensitivity to Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC). Loss leads increased levels H3K27me3 on promoter CD38 , resulting a marked downregulation...
Immunogenic cell death (ICD) is a form of by which cancer treatments can induce clinically relevant antitumor immune response in broad range cancers. In multiple myeloma (MM), the proteasome inhibitor bortezomib an ICD inducer and creates durable therapeutic responses patients. However, eventual relapse resistance to appear inevitable. Here, integrating patient transcriptomic data with analysis calreticulin (CRT) protein interactors, we found that GABA type A receptor-associated (GABARAP)...
// Lavinia Raimondi 1 , Nicola Amodio Maria Teresa Di Martino Emanuela Altomare Marzia Leotta Daniele Caracciolo Annamaria Gullà Antonino Neri 2 Simona Taverna 3 Patrizia D'Aquila 4 Riccardo Alessandro Antonio Giordano 5 Pierosandro Tagliaferri and Pierfrancesco Tassone 1,5 . Department of Experimental Clinical Medicine, Magna Graecia University Medical Oncology Unit, T. Campanella Cancer Center, Salvatore Venuta Campus, Catanzaro, Italy Sciences Milan, Hematology1, IRCCS Policlinico...
Background & Aim The miR-221/222 cluster is upregulated in malignant plasma cells from multiple myeloma (MM) patients harboring the t(4;14) translocation. We previously reported that silencing of by an antisense oligonucleotide induces anti-MM activity and upregulates canonical targets. vivo anti-tumor occurred when inhibitors were delivered directly into MM xenografts. aim present study was to evaluate a novel phosphorothioate modified backbone 13-mer locked nucleic acid...
Abstract Purpose: BRD9 is a defining component of the noncanonical SWI/SNF complex, which regulates gene expression by controlling chromatin dynamics. Although recent studies have found an oncogenic role for in multiple cancer types including myeloma, its clinical significance and mechanism not yet been elucidated. Here, we sought to identify biological impact may contribute development novel therapeutic strategies. Experimental Design: We performed integrated analyses vitro vivo using...
Dendritic cells (DCs) have a key role in regulating tumor immunity, cell growth and drug resistance. We hypothesized that multiple myeloma (MM) might recruit reprogram DCs to tumor-permissive phenotype by changes within their microRNA (miRNA) network. By analyzing six different miRNA-profiling data sets, miR-29b was identified as the only miRNA upregulated normal mature significantly downregulated tumor-associated DCs. This finding validated primary co-cultured vitro with MM lines bone...